Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study
DOI:
https://doi.org/10.2340/1651-226X.2024.40413Keywords:
metaplastic breast cancer, systemic treatment, chemotherapy, disease-free survival, overall survivalAbstract
Background and purpose: Metaplastic breast carcinoma (BC-Mp) is an uncommon subtype that poses unique challenges. The limited information on patient prognosis and therapeutic strategies motivated our research initiative. We aimed to assess disease-free survival (DFS), overall survival (OS), and influential factors in patients with nonmetastatic BC-Mp.
Materials and methods: In this multicenter retrospective cohort study, clinicopathological data for nonmetastatic BC-Mp patients treated at four oncology units in Poland (2012–2022) were gathered.
Results: Among 115 women (median age 61, range: 28–91), the median tumor size was 40 mm (range 20–130); 30% of patients exhibited positive local lymph nodes. The majority of patients presented with stage II (46%) and triple-negative breast cancer (TNBC) (84%). Radiotherapy was administered to 61% of patients. Surgical procedures included breast-conserving surgery in 31% of patients and mastectomy in 68%. Eighty-three per cent of patients received chemotherapy. The median estimated DFS and OS were 59 and 68 months, respectively. Multivariable analysis revealed that tumor size influenced DFS and OS (Hazard ratios [HR] = 1.02, 95%CI 0.01–0.03 for both endpoints) and taxanes application improved DFS (HR = 0.47, 95%CI 0.24–0.93), but other factors did not. For patients receiving neoadjuvant systemic therapy (N = 51), taxanes improved DFS and OS according to univariable analysis.
Interpretation: Our findings highlight poor DFS and OS regardless of receiving optimal treatment, emphasizing the need for tailored therapeutic strategies for BC-Mp patients. Taxanes appear promising in a neoadjuvant setting, particularly within the current standard of care for the TNBC subtype.
Downloads
References
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol 2024;35(2):159–82.https://doi.org/10.1016/j.annonc.2023.11.016
Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183:1113–24.
https://doi.org/10.1016/j.ajpath.2013.08.002
Pathology Outlines – Metaplastic [Internet]. n.d. [cited 2024 Jan 10]. Available from: https://www.pathologyoutlines.com/topic/breastmalignantmetaplastic.html
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77:181–5.
https://doi.org/10.1111/HIS.14091
Song Y, Liu X, Zhang G, Song H, Ren Y, He X, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013;11:1–9.
https://doi.org/10.1186/1477-7819-11-129
Wong W, Brogi E, Reis-Filho JS, Plitas G, Robson M, Norton L, et al. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer. 2021;7:96.
https://doi.org/10.1038/s41523-021-00302-z
Zhang Y, Lv F, Yang Y, Qian X, Lang R, Fan Y, et al. Clinicopathological features and prognosis of metaplastic breast carcinoma: experience of a major Chinese Cancer Center. PLoS One. 2015;10:e0131409.
https://doi.org/10.1371/journal.pone.0131409
He X, Ji J, Dong R, Liu H, Dai X, Wang C, et al. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis. Breast Cancer Res Treat. 2019;173:329–41.
https://doi.org/10.1007/S10549-018-5005-6
Murray-Stewart T, Papatheodoridi A, Papamattheou E, Marinopoulos S, Ntanasis-Stathopoulos I, Dimitrakakis C, et al. Metaplastic carcinoma of the breast: case series of a single institute and review of the literature. Med Sci. 2023;11:35.
https://doi.org/10.3390/medsci11020035
Zheng C, Fu C, Wen Y, Liu J, Lin S, Han H, et al. Clinical characteristics and overall survival prognostic nomogram for metaplastic breast cancer. Front Oncol. 2023;13:1030124.
https://doi.org/10.3389/fonc.2023.1030124
Lan T, Lu Y, Zheng R, Shao X, Luo H, He J, et al. The role of adjuvant chemotherapy in metaplastic breast carcinoma: a competing risk analysis of the SEER database. Front Oncol. 2021;11:572230.
https://doi.org/10.3389/fonc.2021.572230
Lee JH, Ryu JM, Lee SK, Chae BJ, Lee JE, Kim SW, et al. Clinical characteristics and prognosis of metaplastic breast cancer compared with invasive ductal carcinoma: a propensity-matched analysis. Cancers (Basel). 2023;15:1556.
https://doi.org/10.3390/cancers15051556
El Zein D, Hughes M, Kumar S, Peng X, Oyasiji T, Jabbour H, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer. 2017;17:382–91.
https://doi.org/10.1016/J.CLBC.2017.04.009
Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019;176:709–16.
https://doi.org/10.1007/S10549-019-05264-2
Samoon Z, Beg M, Idress R, Jabbar A. Survival and treatment outcomes of metaplastic breast carcinoma: single tertiary care center experience in Pakistan. Indian J Cancer. 2019;56:124–9.
https://doi.org/10.4103/IJC.IJC_731_18
Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, et al. Molecular characterization and prospective evaluation of pathologic response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res. 2022;28:2878–89.
https://doi.org/10.1158/1078-0432.CCR-21-3100
McMullen ER, Zoumberos NA, Kleer CG. Metaplastic breast carcinoma: update on histopathology and molecular alterations. Arch Pathol Lab Med. 2019;143:1492–6.
https://doi.org/10.5858/arpa.2019-0396-RA
Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.
https://doi.org/10.1200/JCO.2009.25.6529
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138:241–56.
https://doi.org/10.5858/arpa.2013-0953-SA
Rakha EA, Coimbra NDM, Hodi Z, Juneinah E, Ellis IO, Lee AHS. Immunoprofile of metaplastic carcinomas of the breast. Histopathology. 2017;70:975–85.
https://doi.org/10.1111/his.13159
Erjan A, Almasri H, Abdel-Razeq H, Al-Masri M, Haddad H, Alnsour A, et al. Metaplastic breast carcinoma: experience of a Tertiary Cancer Center in the Middle East. Cancer Contr. 2021;28:1–8.
https://doi.org/10.1177/10732748211004889
Leyrer CM, Berriochoa CA, Agrawal S, Donaldson A, Calhoun BC, Shah C, et al. Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Res Treat. 2017;165:499–504.
https://doi.org/10.1007/S10549-017-4367-5
Ismail Y, Kamal A, Allam R, Zakaria AS. The conundrum of metaplastic breast cancer: a single Egyptian institution retrospective 10-year experience (2011–2020). J Egypt Natl Canc Inst. 2023;35:16.
https://doi.org/10.1186/S43046-023-00178-Z
Papatheodoridi A, Papamattheou E, Marinopoulos S, Ntanasis-Stathopoulos I, Dimitrakakis C, Giannos A, et al. Metaplastic carcinoma of the breast: case series of a single institute and review of the literature. Med Sci. 2023;11:35.
https://doi.org/10.3390/MEDSCI11020035
Hu J, Lang R, Zhao W, Jia Y, Tong Z, Shi Y. The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer. Breast Cancer Res Treat. 2023;200:23–36.
https://doi.org/10.1007/S10549-023-06945-9
Püsküllüoğlu M, Świderska K, Konieczna A, Rudnicki W, Pacholczak-Madej R, Kunkiel M, et al. Discrepancy between tumor size assessed by full-field digital mammography or ultrasonography (cT) and pathology (pT) in a multicenter series of breast metaplastic carcinoma patients. Cancers. 2024;16:188.
https://doi.org/10.3390/cancers16010188
Han M, Salamat A, Zhu L, Zhang H, Clark BZ, Dabbs DJ, et al. Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy. Modern Pathol. 2019;32:807–16.
https://doi.org/10.1038/s41379-019-0208-x
Püsküllüoğlu M, Swiderska K, Konieczna A, Streb J, Grela-Wojewoda A, Rudzinska A, et al. Clinical analysis of metaplastic breast carcinoma with distant metastases: a multi‑centre experience. Oncol Lett. 2024;27:198.
https://doi.org/10.3892/OL.2024.14331
Balasubramanian A, Iyer P, Ranganathan R, Murhekar K, Dhanushkodi M, Ganesarajah S, et al. Metaplastic carcinoma of the breast: real-world outcome from a tertiary cancer centre in India. Ecancermedicalscience. 2022;16:1429.
https://doi.org/10.3332/ECANCER.2022.1429
Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol. 1987;11:918–29.
https://doi.org/10.1097/00000478-198712000-00002
Youssef I, Lee A, Kukunoor S, Taiwo E, Luhrs CA, Schreiber D. Patterns of care and survival of metastatic metaplastic breast cancer patients. Cureus. 2020;12:e10339.
https://doi.org/10.7759/cureus.10339
Ong CT, Campbell BM, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, et al. Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a National Oncology Database. Ann Surg Oncol. 2018;25:2249–60.
https://doi.org/10.1245/s10434-018-6533-3
Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer. 2015;112:283–9.
https://doi.org/10.1038/BJC.2014.592
Haque W, Verma V, Schwartz MR, Lim B, Mangalampalli N, Butler EB, et al. Neoadjuvant chemotherapy for metaplastic breast cancer: response rates, management, and outcomes. Clin Breast Cancer. 2022;22:e691–9.
https://doi.org/10.1016/J.CLBC.2022.01.006
Aydiner A, Sen F, Tambas M, Ciftci R, Eralp Y, Saip P, et al. Metaplastic breast carcinoma versus triple-negative breast cancer: survival and response to treatment. Medicine. 2015;94:e2341.
https://doi.org/10.1097/MD.0000000000002341
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.
https://doi.org/10.1056/NEJMOA1910549
Xia LY, Xu WY, Hu QL. The different outcomes between breast-conserving surgery plus radiotherapy and mastectomy in metaplastic breast cancer: a population-based study. PLoS One. 2021;16.
https://doi.org/10.1371/journal.pone.0256893
Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120:627–37.
https://doi.org/10.1007/S10549-010-0780-8
Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat. 2012;131:41–8.
https://doi.org/10.1007/S10549-011-1393-6
Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011;18:94–103.
https://doi.org/10.1245/S10434-010-1198-6
Haque W, Verma V, Naik N, Butler EB, Teh BS. Metaplastic breast cancer: practice patterns, outcomes, and the role of radiotherapy. Ann Surg Oncol. 2018;25:928–36.
https://doi.org/10.1245/S10434-017-6316-2
Haque W, Verma V, Butler EB, Teh BS. Omission of radiotherapy in elderly women with early stage metaplastic breast cancer. Breast. 2018;38:154–9.
https://doi.org/10.1016/J.BREAST.2018.01.005
Leo F, Bartels S, Mägel L, Framke T, Büsche G, Jonigk D, et al. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Arch. 2016;469:191–201.
https://doi.org/10.1007/S00428-016-1950-9
ClinicalTrials.gov [Internet]. n.d. [cited 2023 Jan 05]. Available from: https://clinicaltrials.gov/
Püsküllüoğlu M, Rudzińska A, Pacholczak-Madej R. Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis. Biochim Biophys Acta Rev Cancer. 2023;1878:188991.
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Mirosława Püsküllüoğlu, Aleksandra Konieczna, Katarzyna Świderska, Joanna Streb, Małgorzata Pieniążek, Aleksandra Grela-Wojewoda, Renata Pacholczak-Madej, Anna Mucha-Małecka, Jerzy W. Mituś, Joanna Szpor, Michał Kunkiel, Agnieszka Rudzińska, Michał Jarząb, Marek Ziobro
This work is licensed under a Creative Commons Attribution 4.0 International License.
